$AMRX
Amneal Pharmaceuticals, Inc. Stock $amrx

$amrx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000172312824000014 Filed on March 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$659.2M	$617.0M	$2.394B
YoY Change	18.23%	1.18%	8.2%
Cost Of Revenue	$421.1M	$427.2M	$1.537B
YoY Change	11.01%	9.8%	8.5%
Gross Profit	$238.1M	$189.8M	$856.7M
YoY Change	33.6%	-13.99%	9.17%
Gross Profit Margin	36.11%	30.77%	35.79%
Selling, General & Admin	$112.6M	$109.5M	$433.5M
YoY Change	10.28%	5.76%	8.46%
% of Gross Profit	47.3%	57.67%	50.6%
Research & Development	$39.30M	$46.09M	$164.0M
YoY Change	1.57%	9.97%	-16.22%
% of Gross Profit	16.51%	24.28%	19.14%
Depreciation & Amortization		$56.93M	$229.4M
YoY Change		-6.75%	236.8%
% of Gross Profit		29.99%	26.78%
Operating Expenses	$151.9M	$141.9M	$581.8M
YoY Change	7.89%	-2.96%	-2.28%
Operating Profit	-$10.75M	$47.97M	$274.8M
YoY Change	-131.19%	-35.63%	-389.53%
Interest Expense	-$65.70M	-$57.26M	-$209.0M
YoY Change	33.23%	23.25%	31.94%
% of Operating Profit		-119.37%	-76.03%
Other Income/Expense, Net	-$64.78M	-$40.39M	-$35.69M
YoY Change	47.64%	-1557.22%	-76.71%
Pretax Income	-$75.52M	-$83.46M	-$40.27M
YoY Change	701.21%	990.28%	-83.77%
Income Tax	$6.200M	$9.883M	$8.452M
% Of Pretax Income
Net Earnings	-$91.64M	-$98.65M	-$83.99M
YoY Change	486.29%	2176.69%	-68.96%
Net Earnings / Revenue	-13.9%	-15.99%	-3.51%
Basic Earnings Per Share	-$0.30		-$0.48
Diluted Earnings Per Share	-$0.30	-$0.40	-$0.48
COMMON SHARES
Basic Shares Outstanding	307.0M shares		176.1M shares
Diluted Shares Outstanding	307.3M shares		176.1M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$91.54M	$91.54M
YoY Change		252.41%	252.41%
Cash & Equivalents	$46.52M	$91.54M	$91.54M
Short-Term Investments
Other Short-Term Assets		$59.28M	$59.28M
YoY Change		1.86%	1.86%
Inventory	$570.7M	$581.4M	$581.4M
Prepaid Expenses
Receivables		$613.7M	$613.7M
Other Receivables	$12.80M	$31.93M	$31.93M
Total Short-Term Assets	$1.380B	$1.378B	$1.378B
YoY Change	5.56%	-2.41%	-2.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$439.8M	$550.1M	$550.1M
YoY Change	-4.93%	17.1%	-6.66%
Goodwill	$598.5M	$598.6M
YoY Change	-0.1%	-0.04%
Intangibles	$859.3M	$890.4M
YoY Change	-18.58%	-18.76%
Long-Term Investments
YoY Change
Other Assets	$73.75M	$55.52M	$55.52M
YoY Change	-14.67%	-46.21%	-46.21%
Total Long-Term Assets	$2.076B	$2.095B	$2.095B
YoY Change	-10.47%	-12.26%	-12.26%
TOTAL ASSETS
Total Short-Term Assets	$1.380B	$1.378B	$1.378B
Total Long-Term Assets	$2.076B	$2.095B	$2.095B
Total Assets	$3.456B	$3.473B	$3.473B
YoY Change	-4.69%	-8.6%	-8.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$175.3M	$143.6M	$143.6M
YoY Change	28.05%	-13.5%	-13.5%
Accrued Expenses		$403.1M	$403.1M
YoY Change		3502.52%	5.24%
Deferred Revenue
YoY Change
Short-Term Debt		$179.0M	$179.0M
YoY Change		198.33%	198.33%
Long-Term Debt Due	$33.66M	$36.59M	$36.59M
YoY Change	12.33%	22.13%	9.4%
Total Short-Term Liabilities	$834.4M	$846.6M	$846.6M
YoY Change	18.57%	12.46%	12.46%
LONG-TERM LIABILITIES
Long-Term Debt	$2.378B	$2.486B	$2.486B
YoY Change	-7.18%	-4.09%	-7.67%
Other Long-Term Liabilities		$78.65M	$78.65M
YoY Change		-10.08%	-45.82%
Total Long-Term Liabilities	$2.639B	$2.565B	$2.565B
YoY Change	-4.42%	-9.62%	-9.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$834.4M	$846.6M	$846.6M
Total Long-Term Liabilities	$2.639B	$2.565B	$2.565B
Total Liabilities	$3.473B	$3.453B	$3.453B
YoY Change	0.25%	-3.83%	-1.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$581.8M	-$490.2M
YoY Change	40.83%	20.68%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$63.72M	$19.78M	$19.78M
YoY Change
Total Liabilities & Shareholders Equity	$3.456B	$3.473B	$3.473B
YoY Change	-4.69%	-8.6%	-8.6%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$91.64M	-$98.65M	-$83.99M
YoY Change	486.29%	2176.69%	-68.96%
Depreciation, Depletion And Amortization		$56.93M	$229.4M
YoY Change		-6.75%	236.8%
Cash From Operating Activities	-$4.410M	$135.8M	$345.6M
YoY Change	-103.16%	-683.13%	430.84%
INVESTING ACTIVITIES
Capital Expenditures	$9.198M	$31.69M	$69.19M
YoY Change	-5.06%	176.4%	49.09%
Acquisitions			$0.00
YoY Change			-100.0%
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$19.76M	-$31.69M	-$69.19M
YoY Change	68.36%	176.4%	-60.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$43.00K	$451.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$23.16M	-100.8M	-212.6M
YoY Change	79.5%	354.87%	99.37%
NET CHANGE
Cash From Operating Activities	-$4.410M	135.8M	345.6M
Cash From Investing Activities	-$19.76M	-31.69M	-69.19M
Cash From Financing Activities	-$23.16M	-100.8M	-212.6M
Net Change In Cash	-$47.49M	3.299M	63.82M
YoY Change	-141.0%	-105.8%	-128.81%
FREE CASH FLOW
Cash From Operating Activities	-$4.410M	$135.8M	$345.6M
Capital Expenditures	$9.198M	$31.69M	$69.19M
Free Cash Flow	-$13.61M	$104.1M	$276.4M
YoY Change	-110.47%	-399.59%	1378.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	14497000	usd
CY2023	amrx	Insurance Recoveries Charges For Property Losses And Associated Expenses Net InsuranceRecoveriesChargesForPropertyLossesAndAssociatedExpensesNet	0	usd
CY2022	amrx	Insurance Recoveries Charges For Property Losses And Associated Expenses Net InsuranceRecoveriesChargesForPropertyLossesAndAssociatedExpensesNet	-1911000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-1824000	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-269930000	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-25000000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-94928000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	152716000	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-136325000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17833000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15330000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-121350000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	344932000	usd
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	11804000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	13163000	usd
CY2021	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	7007000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-8618000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28412000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-355000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5119000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-153199000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	31366000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001723128
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0	usd
CY2023	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#AssetImpairmentCharges http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold
CY2022	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#AssetImpairmentCharges http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold
CY2021	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#AssetImpairmentCharges http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38485
CY2023	dei	Entity Registrant Name EntityRegistrantName	Amneal Pharmaceuticals, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	93-4225266
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08807
CY2023	dei	City Area Code CityAreaCode	908
CY2023	dei	Local Phone Number LocalPhoneNumber	947-3120
CY2023	dei	Security12b Title Security12bTitle	Class A Common Stock, par value $0.01 per share
CY2023	dei	Trading Symbol TradingSymbol	AMRX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	464000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	307006908	shares
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Iselin, NJ
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2393607000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2212304000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2093669000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1573042000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1427596000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1324696000	usd
CY2023	us-gaap	Gross Profit GrossProfit	820565000	usd
CY2022	us-gaap	Gross Profit GrossProfit	784708000	usd
CY2021	us-gaap	Gross Profit GrossProfit	768973000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	429675000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	399700000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	365504000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	163950000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	195688000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	201847000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	30800000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	12970000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	710000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	3828000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	4358000	usd
CY2021	us-gaap	Royalty Expense RoyaltyExpense	7716000	usd
CY2023	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	0	usd
CY2022	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	709000	usd
CY2021	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	8055000	usd
CY2023	us-gaap	Restructuring Charges RestructuringCharges	1749000	usd
CY2022	us-gaap	Restructuring Charges RestructuringCharges	1421000	usd
CY2021	us-gaap	Restructuring Charges RestructuringCharges	1857000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-731000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-200000	usd
CY2021	amrx	Insurance Recoveries Charges For Property Losses And Associated Expenses Net InsuranceRecoveriesChargesForPropertyLossesAndAssociatedExpensesNet	5368000	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1138000	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	3960000	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	0	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	204374000	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-210629000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-158377000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1671000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-12364000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-40805000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-291000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	35271000	usd
CY2023	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	-83993000	usd
CY2022	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	-129548000	usd
CY2021	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	10624000	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	438000	usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-83993000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-129986000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	10624000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2023	us-gaap	Profit Loss ProfitLoss	-48722000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	35271000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-125241000	usd
CY2023	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	-83993000	usd
CY2022	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	-129548000	usd
CY2021	amrx	Net Income Loss Attributable To Parent Before Accretion Of Redeemable Noncontrolling Interest NetIncomeLossAttributableToParentBeforeAccretionOfRedeemableNoncontrollingInterest	10624000	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	438000	usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-83993000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-129986000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	10624000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-8618000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-48497000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	97059000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	42430000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	3366000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	0	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-9875000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	35292000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	17095000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-43047000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	34876000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	16717000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-127040000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-95110000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	27341000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	91542000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25976000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	7565000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9251000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	581384000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	530735000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	82685000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	103565000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1377863000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1411818000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	447574000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	469815000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	598629000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	598853000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	890423000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1096093000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55517000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	103217000	usd
CY2023Q4	us-gaap	Assets Assets	3472569000	usd
CY2022Q4	us-gaap	Assets Assets	3799341000	usd
CY2023Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	76988000	usd
CY2022Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	107483000	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	179000000	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	60000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	34125000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	29961000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	846595000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	752800000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2386004000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2591981000	usd
CY2023Q4	us-gaap	Other Notes Payable OtherNotesPayable	41447000	usd
CY2022Q4	us-gaap	Other Notes Payable OtherNotesPayable	39706000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2564670000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2837613000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	41293000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	24949000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	539240000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	691629000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-490176000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-406183000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-32349000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9939000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	19781000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	298421000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	230000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-114442000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20011000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	183979000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3472569000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3799341000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	183979000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	24949000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-79265000	usd
CY2023	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	30543000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1059000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26822000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	451000	usd
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-2370000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-48497000	usd
CY2023	amrx	Temporary Equity Tax Distribution TemporaryEquityTaxDistribution	14199000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	3366000	usd
CY2023	amrx	Effect Of The Reorganization Value EffectOfTheReorganizationValue	0	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20011000	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	41293000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	366973000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	16907000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-270584000	usd
CY2022	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	15795000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-26891000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31847000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	662000	usd
CY2022	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-3562000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	97059000	usd
CY2022	amrx	Temporary Equity Tax Distribution TemporaryEquityTaxDistribution	6914000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	883000	usd
CY2022	amrx	Temporary Equity Reclassification Of Redeemable Non Controlling Interest TemporaryEquityReclassificationOfRedeemableNonControllingInterest	883000	usd
CY2022	amrx	Temporary Equity Increase From Business Combination TemporaryEquityIncreaseFromBusinessCombination	-1722000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	183979000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	24949000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	853000	usd
CY2021	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-2713000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	42430000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	366973000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	16907000	usd
CY2021	amrx	Temporary Equity Tax Distribution TemporaryEquityTaxDistribution	3646000	usd
CY2021	amrx	Temporary Equity Increase From Business Combination TemporaryEquityIncreaseFromBusinessCombination	1742000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-48722000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-254789000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	20170000	usd
CY2023	amrx	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	229400000	usd
CY2022	amrx	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	240175000	usd
CY2021	amrx	Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts	233406000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	768000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-15190000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-175000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8182000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8595000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	9203000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-40805000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-291000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	66932000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	24081000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	23402000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-14497000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	731000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	200000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	26822000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	31847000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	28412000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	74686000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	51096000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	54660000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1000000	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	5000000	usd
CY2023	amrx	Noncash Property Losses NoncashPropertyLosses	0	usd
CY2022	amrx	Noncash Property Losses NoncashPropertyLosses	0	usd
CY2021	amrx	Noncash Property Losses NoncashPropertyLosses	5152000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-9923000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8828000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5633000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-126289000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	79717000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23621000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	126182000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	102396000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	49015000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-37814000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9882000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	21981000	usd
CY2023	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	490000	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-646000	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-7311000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-94446000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	109568000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-43932000	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	9829000	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	2072000	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-2355000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	345577000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	65100000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	241820000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	43216000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46407000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47728000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	22388000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	41800000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1700000	usd
CY2023	amrx	Payments To Acquire Property Plant And Equipment Deposits PaymentsToAcquirePropertyPlantAndEquipmentDeposits	3585000	usd
CY2022	amrx	Payments To Acquire Property Plant And Equipment Deposits PaymentsToAcquirePropertyPlantAndEquipmentDeposits	2388000	usd
CY2021	amrx	Payments To Acquire Property Plant And Equipment Deposits PaymentsToAcquirePropertyPlantAndEquipmentDeposits	3211000	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	84714000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	146543000	usd
CY2023	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	0	usd
CY2022	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	1000000	usd
CY2021	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	5000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-69189000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-174309000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-194182000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	162415000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1663000	usd
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2023	amrx	Repayments Of Long Term Debt Revolving Credit Facility And Financing Lease Obligations RepaymentsOfLongTermDebtRevolvingCreditFacilityAndFinancingLeaseObligations	-414080000	usd
CY2022	amrx	Repayments Of Long Term Debt Revolving Credit Facility And Financing Lease Obligations RepaymentsOfLongTermDebtRevolvingCreditFacilityAndFinancingLeaseObligations	-123272000	usd
CY2021	amrx	Repayments Of Long Term Debt Revolving Credit Facility And Financing Lease Obligations RepaymentsOfLongTermDebtRevolvingCreditFacilityAndFinancingLeaseObligations	-78086000	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	217732000	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2023	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	219000000	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	85000000	usd
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	451000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	662000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	853000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2378000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3571000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2664000	usd
CY2023	amrx	Payment Of Deferred Consideration For Acquisition Related Party PaymentOfDeferredConsiderationForAcquisitionRelatedParty	0	usd
CY2022	amrx	Payment Of Deferred Consideration For Acquisition Related Party PaymentOfDeferredConsiderationForAcquisitionRelatedParty	44498000	usd
CY2021	amrx	Payment Of Deferred Consideration For Acquisition Related Party PaymentOfDeferredConsiderationForAcquisitionRelatedParty	0	usd
CY2023	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	0	usd
CY2022	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	1722000	usd
CY2021	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	0	usd
CY2023	amrx	Tax Distribution To Noncontrolling Interest Financing Activities TaxDistributionToNoncontrollingInterestFinancingActivities	70883000	usd
CY2022	amrx	Tax Distribution To Noncontrolling Interest Financing Activities TaxDistributionToNoncontrollingInterestFinancingActivities	17556000	usd
CY2021	amrx	Tax Distribution To Noncontrolling Interest Financing Activities TaxDistributionToNoncontrollingInterestFinancingActivities	57132000	usd
CY2023	amrx	Finance Lease Principal Payments Related Party FinanceLeasePrincipalPaymentsRelatedParty	0	usd
CY2022	amrx	Finance Lease Principal Payments Related Party FinanceLeasePrincipalPaymentsRelatedParty	0	usd
CY2021	amrx	Finance Lease Principal Payments Related Party FinanceLeasePrincipalPaymentsRelatedParty	93000	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-212573000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-106620000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-138122000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5683000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	63880000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-221512000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-90382000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35227000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	256739000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	347121000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99107000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35227000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	256739000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	91542000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25976000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	247790000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	7565000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9251000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	8949000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99107000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35227000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	256739000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	192806000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	142722000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	121747000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-2496000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-12649000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-15558000	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	14162000	usd
CY2023	amrx	Noncash Or Part Noncash Acquisition Deferred Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionDeferredConsiderationForAcquisitionRelatedParty	0	usd
CY2022	amrx	Noncash Or Part Noncash Acquisition Deferred Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionDeferredConsiderationForAcquisitionRelatedParty	0	usd
CY2021	amrx	Noncash Or Part Noncash Acquisition Deferred Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionDeferredConsiderationForAcquisitionRelatedParty	30099000	usd
CY2023	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisition	0	usd
CY2022	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisition	8796000	usd
CY2021	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisition	0	usd
CY2023	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisitionRelatedParty	0	usd
CY2022	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisitionRelatedParty	0	usd
CY2021	amrx	Noncash Or Part Noncash Acquisition Contingent Consideration For Acquisition Related Party NoncashOrPartNoncashAcquisitionContingentConsiderationForAcquisitionRelatedParty	5700000	usd
CY2023	amrx	Intangible Asset Expenditures Incurred But Not Yet Paid IntangibleAssetExpendituresIncurredButNotYetPaid	2100000	usd
CY2022	amrx	Intangible Asset Expenditures Incurred But Not Yet Paid IntangibleAssetExpendituresIncurredButNotYetPaid	0	usd
CY2021	amrx	Intangible Asset Expenditures Incurred But Not Yet Paid IntangibleAssetExpendituresIncurredButNotYetPaid	300000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.</span></div>
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	7600000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9300000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior period balances related to cost of goods sold impairment charges of $11.1 million and $22.7 million, formerly included in a separate caption in the consolidated statements of operations for the years ended December 31, 2022 and 2021, respectively, have been reclassified to be included within the caption cost of goods sold in the consolidated statements of operations to conform with the current period presentation. This reclassification did not impact gross profit or net income.</span></div>
CY2022	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	11100000	usd
CY2021	amrx	Cost Of Goods And Services Sold Impairment Charges CostOfGoodsAndServicesSoldImpairmentCharges	22700000	usd
CY2022	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	700000	usd
CY2021	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	8100000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2393607000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2212304000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2093669000	usd
CY2023	us-gaap	Other Operating Income OtherOperatingIncome	1200000	usd
CY2022	us-gaap	Other Operating Income OtherOperatingIncome	4000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	566500000	usd
	amrx	Percentage Of Tax Benefits Under Tax Receivable Agreement PercentageOfTaxBenefitsUnderTaxReceivableAgreement	0.85
CY2019	amrx	Reversal Of Accrued Tax Receivable Agreement Liability ReversalOfAccruedTaxReceivableAgreementLiability	192800000	usd
	amrx	Percentage Of Tax Benefits Under Tax Receivable Agreement PercentageOfTaxBenefitsUnderTaxReceivableAgreement	0.85
CY2023Q4	amrx	Percentage Of Tax Benefits Under Tax Receivable Agreement PercentageOfTaxBenefitsUnderTaxReceivableAgreement	0.75
CY2023Q4	amrx	Liabilities Under Tax Receivable Agreement Noncurrent LiabilitiesUnderTaxReceivableAgreementNoncurrent	185200000	usd
CY2023Q4	amrx	Liabilities Under Tax Receivable Agreement Noncurrent LiabilitiesUnderTaxReceivableAgreementNoncurrent	185200000	usd
CY2023Q4	amrx	Tax Receivable Agreement Liability TaxReceivableAgreementLiability	3700000	usd
CY2022Q4	amrx	Tax Receivable Agreement Liability TaxReceivableAgreementLiability	600000	usd
CY2023Q4	amrx	Tax Receivable Agreement Expense Other Income Net TaxReceivableAgreementExpenseOtherIncomeNet	3100000	usd
CY2022Q4	amrx	Tax Receivable Agreement Expense Other Income Net TaxReceivableAgreementExpenseOtherIncomeNet	600000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8500000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.210
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6700000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.027
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11200000	usd
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.357
CY2023Q4	amrx	Income Tax Examination Cares Act Carryback Amount Sustained IncomeTaxExaminationCARESActCarrybackAmountSustained	345000000	usd
CY2023	amrx	Income Tax Returns Examination Period IncomeTaxReturnsExaminationPeriod	P3Y
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40270000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-248127000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	31366000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.043
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.210
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.027
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.357
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	434895000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	416588000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2470000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-1073000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1311000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	5982000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	7735000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	9885000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	8452000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6662000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	11196000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	-0.055
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	-0.008
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	0.042
CY2023	amrx	Effective Income Tax Rate Reconciliation Loss No Benefit Recognized Percent EffectiveIncomeTaxRateReconciliationLossNoBenefitRecognizedPercent	0.145
CY2022	amrx	Effective Income Tax Rate Reconciliation Loss No Benefit Recognized Percent EffectiveIncomeTaxRateReconciliationLossNoBenefitRecognizedPercent	-0.107
CY2021	amrx	Effective Income Tax Rate Reconciliation Loss No Benefit Recognized Percent EffectiveIncomeTaxRateReconciliationLossNoBenefitRecognizedPercent	0.064
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.195
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.034
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.173
CY2023	amrx	Effective Income Tax Rate Reconciliation Permanent Book Tax Differences Percent EffectiveIncomeTaxRateReconciliationPermanentBookTaxDifferencesPercent	-0.021
CY2022	amrx	Effective Income Tax Rate Reconciliation Permanent Book Tax Differences Percent EffectiveIncomeTaxRateReconciliationPermanentBookTaxDifferencesPercent	-0.003
CY2021	amrx	Effective Income Tax Rate Reconciliation Permanent Book Tax Differences Percent EffectiveIncomeTaxRateReconciliationPermanentBookTaxDifferencesPercent	0.048
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.077
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.003
CY2023	amrx	Effective Income Tax Rate Reconciliation Deferred Tax Adjustment Percent EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentPercent	-0.057
CY2022	amrx	Effective Income Tax Rate Reconciliation Deferred Tax Adjustment Percent EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentPercent	0
CY2021	amrx	Effective Income Tax Rate Reconciliation Deferred Tax Adjustment Percent EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentPercent	0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.323
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.103
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.135
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.011
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	422812000	usd
CY2023	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Current Year Net Operating Losses And Temporary Differences ValuationAllowanceDeferredTaxAssetIncreaseDecreaseCurrentYearNetOperatingLossesAndTemporaryDifferences	23078000	usd
CY2022	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Current Year Net Operating Losses And Temporary Differences ValuationAllowanceDeferredTaxAssetIncreaseDecreaseCurrentYearNetOperatingLossesAndTemporaryDifferences	25589000	usd
CY2021	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Current Year Net Operating Losses And Temporary Differences ValuationAllowanceDeferredTaxAssetIncreaseDecreaseCurrentYearNetOperatingLossesAndTemporaryDifferences	-10828000	usd
CY2023	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Share Based Compensation ValuationAllowanceDeferredTaxAssetIncreaseDecreaseShareBasedCompensation	1652000	usd
CY2022	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Share Based Compensation ValuationAllowanceDeferredTaxAssetIncreaseDecreaseShareBasedCompensation	224000	usd
CY2021	amrx	Valuation Allowance Deferred Tax Asset Increase Decrease Share Based Compensation ValuationAllowanceDeferredTaxAssetIncreaseDecreaseShareBasedCompensation	5513000	usd
CY2023	amrx	Valuation Allowance Increase Decrease Recorded Against Goodwill ValuationAllowanceIncreaseDecreaseRecordedAgainstGoodwill	0	usd
CY2022	amrx	Valuation Allowance Increase Decrease Recorded Against Goodwill ValuationAllowanceIncreaseDecreaseRecordedAgainstGoodwill	-1590000	usd
CY2021	amrx	Valuation Allowance Increase Decrease Recorded Against Goodwill ValuationAllowanceIncreaseDecreaseRecordedAgainstGoodwill	0	usd
CY2023	amrx	Valuation Allowance Increase Decrease Recorded Against Additional Paid In Capital ValuationAllowanceIncreaseDecreaseRecordedAgainstAdditionalPaidInCapital	96316000	usd
CY2022	amrx	Valuation Allowance Increase Decrease Recorded Against Additional Paid In Capital ValuationAllowanceIncreaseDecreaseRecordedAgainstAdditionalPaidInCapital	2720000	usd
CY2021	amrx	Valuation Allowance Increase Decrease Recorded Against Additional Paid In Capital ValuationAllowanceIncreaseDecreaseRecordedAgainstAdditionalPaidInCapital	2842000	usd
CY2023	amrx	Valuation Allowance Increase Decrease Recorded Against Other Comprehensive Income ValuationAllowanceIncreaseDecreaseRecordedAgainstOtherComprehensiveIncome	10603000	usd
CY2022	amrx	Valuation Allowance Increase Decrease Recorded Against Other Comprehensive Income ValuationAllowanceIncreaseDecreaseRecordedAgainstOtherComprehensiveIncome	-8636000	usd
CY2021	amrx	Valuation Allowance Increase Decrease Recorded Against Other Comprehensive Income ValuationAllowanceIncreaseDecreaseRecordedAgainstOtherComprehensiveIncome	-3751000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	566544000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	434895000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	416588000	usd
CY2023Q4	amrx	Deferred Tax Assets Partnership Interest DeferredTaxAssetsPartnershipInterest	318140000	usd
CY2022Q4	amrx	Deferred Tax Assets Partnership Interest DeferredTaxAssetsPartnershipInterest	203336000	usd
CY2023Q4	amrx	Deferred Tax Assets Projected Imputed Interest On Tax Receivable Agreement DeferredTaxAssetsProjectedImputedInterestOnTaxReceivableAgreement	22730000	usd
CY2022Q4	amrx	Deferred Tax Assets Projected Imputed Interest On Tax Receivable Agreement DeferredTaxAssetsProjectedImputedInterestOnTaxReceivableAgreement	25255000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	74340000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	82338000	usd
CY2023Q4	amrx	Deferred Tax Assets Tax Credit Carryforwards Interest DeferredTaxAssetsTaxCreditCarryforwardsInterest	72513000	usd
CY2022Q4	amrx	Deferred Tax Assets Tax Credit Carryforwards Interest DeferredTaxAssetsTaxCreditCarryforwardsInterest	54996000	usd
CY2023Q4	amrx	Deferred Tax Assets Capitalized Costs DeferredTaxAssetsCapitalizedCosts	2537000	usd
CY2022Q4	amrx	Deferred Tax Assets Capitalized Costs DeferredTaxAssetsCapitalizedCosts	2505000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	648000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	431000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14672000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5737000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	21901000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	23967000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	39063000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	36330000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	566544000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	434895000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	566544000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	434895000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3700000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3600000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5500000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3600000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3500000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	5400000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	-700000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	100000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	100000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	100000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	800000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3616000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5489000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5368000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	170000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	110000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	131000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	51000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1983000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	10000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3735000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3616000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5489000	usd
CY2023Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	130800000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-83993000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-129986000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	10624000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	176136000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150944000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	148922000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	176136000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150944000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	151821000	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.86
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	217744000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	224607000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	59563000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	58522000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	304077000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	247606000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	581384000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	530735000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2200000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1821000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	8334000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	8090000	usd
CY2023Q4	amrx	Prepaid Regulatory Fees Current PrepaidRegulatoryFeesCurrent	6331000	usd
CY2022Q4	amrx	Prepaid Regulatory Fees Current PrepaidRegulatoryFeesCurrent	5298000	usd
CY2023Q4	amrx	Income And Other Taxes Receivable IncomeAndOtherTaxesReceivable	13168000	usd
CY2022Q4	amrx	Income And Other Taxes Receivable IncomeAndOtherTaxesReceivable	12881000	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	11899000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	16593000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	9929000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	33133000	usd
CY2023Q4	amrx	Chargebacks Receivable Current ChargebacksReceivableCurrent	7876000	usd
CY2022Q4	amrx	Chargebacks Receivable Current ChargebacksReceivableCurrent	8605000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	22948000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	17144000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	82685000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	103565000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	955601000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	915786000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	508027000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	445971000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	447574000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	469815000	usd
CY2023	us-gaap	Depreciation Depreciation	66200000	usd
CY2022	us-gaap	Depreciation Depreciation	68100000	usd
CY2021	us-gaap	Depreciation Depreciation	60700000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	598853000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	593017000	usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	7553000	usd
CY2023	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	0	usd
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	3075000	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-224000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-4792000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	598629000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	598853000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	amrx	Goodwill Impairment Test Increase Of Assumed Discount Rates GoodwillImpairmentTestIncreaseOfAssumedDiscountRates	0.0500
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1310771000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	776193000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	534578000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1356562000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	651224000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	705338000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	355845000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	355845000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	390755000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	390755000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1666616000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	776193000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	890423000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1747317000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	651224000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1096093000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	66900000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	24100000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	23400000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	163200000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172100000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172700000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	355800000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	159059000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	119404000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	70708000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	50380000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	31656000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	103371000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	534578000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2543626000	usd
CY2022	us-gaap	Lease Cost LeaseCost	27116000	usd
CY2021	us-gaap	Lease Cost LeaseCost	24371000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55517000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	103217000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2635876000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	123497000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	13934000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	2420129000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	2621942000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	34125000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	29961000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2386004000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2591981000	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	11100000	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	7600000	usd
CY2023Q4	amrx	Employee Benefit Liability Noncurrent EmployeeBenefitLiabilityNoncurrent	10200000	usd
CY2022Q4	amrx	Employee Benefit Liability Noncurrent EmployeeBenefitLiabilityNoncurrent	9100000	usd
CY2023	amrx	Operating And Finance Lease Expense OperatingAndFinanceLeaseExpense	21700000	usd
CY2022	amrx	Operating And Finance Lease Expense OperatingAndFinanceLeaseExpense	22600000	usd
CY2021	amrx	Operating And Finance Lease Expense OperatingAndFinanceLeaseExpense	19800000	usd
CY2023	amrx	Operating Short Term And Variable Lease Cost OperatingShortTermAndVariableLeaseCost	16734000	usd
CY2022	amrx	Operating Short Term And Variable Lease Cost OperatingShortTermAndVariableLeaseCost	17800000	usd
CY2021	amrx	Operating Short Term And Variable Lease Cost OperatingShortTermAndVariableLeaseCost	15057000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4972000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4808000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4713000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4583000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4508000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4601000	usd
CY2023	amrx	Finance Lease Cost FinanceLeaseCost	9555000	usd
CY2022	amrx	Finance Lease Cost FinanceLeaseCost	9316000	usd
CY2021	amrx	Finance Lease Cost FinanceLeaseCost	9314000	usd
CY2023	us-gaap	Lease Cost LeaseCost	26289000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43283000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	56121000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	48914000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	59230000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	61033000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	64257000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4583000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4539000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	16036000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	16217000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3588000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3484000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	773000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7504000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	856000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	4606000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P18Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P19Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.073
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.072
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15978000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	6856000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	14544000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	6874000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10693000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	6140000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7742000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	5647000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5467000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	5647000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6916000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	79573000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	61340000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	110737000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12426000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	49704000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	48914000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	61033000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15843000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	7976000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	16558000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	6913000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	14264000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	6466000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10393000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	5989000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7420000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	5645000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	11550000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	85220000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	76028000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	118209000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16798000	usd
CY2022Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	53952000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	59230000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	64257000	usd
CY2023Q4	us-gaap	Interest Rate Cash Flow Hedge Asset At Fair Value InterestRateCashFlowHedgeAssetAtFairValue	37089000	usd
CY2023Q4	amrx	Deferred Compensation Plan Liabilities Fair Value Disclosures DeferredCompensationPlanLiabilitiesFairValueDisclosures	9100000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	921000	usd
CY2022Q4	us-gaap	Interest Rate Cash Flow Hedge Asset At Fair Value InterestRateCashFlowHedgeAssetAtFairValue	85586000	usd
CY2022Q4	amrx	Deferred Compensation Plan Liabilities Fair Value Disclosures DeferredCompensationPlanLiabilitiesFairValueDisclosures	9674000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	15427000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax	3400000	usd
CY2023	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	26200000	usd
CY2023Q4	us-gaap	Aoci Loss Cash Flow Hedge Cumulative Gain Loss After Tax AociLossCashFlowHedgeCumulativeGainLossAfterTax	33700000	usd
CY2022Q4	us-gaap	Aoci Loss Cash Flow Hedge Cumulative Gain Loss After Tax AociLossCashFlowHedgeCumulativeGainLossAfterTax	85600000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-1800000	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-269900000	usd
CY2023Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	76988000	usd
CY2022Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	107483000	usd
CY2023Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	316000	usd
CY2022Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	49442000	usd
CY2023Q4	amrx	Litigation Settlement Initial Discount Amount LitigationSettlementInitialDiscountAmount	2200000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	56700000	usd
CY2022	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	10600000	usd
CY2021	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	53500000	usd
CY2022Q4	amrx	Liability For Tax Distributions Payable To Members LiabilityForTaxDistributionsPayableToMembers	0	usd
CY2023Q4	amrx	Liability For Tax Distributions Payable To Members LiabilityForTaxDistributionsPayableToMembers	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	34876000	usd
CY2022	amrx	Changes In Reallocation Of Ownership Interests ChangesInReallocationOfOwnershipInterests	-110000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-39681000	usd
CY2023	amrx	Changes In Reallocation Of Ownership Interests ChangesInReallocationOfOwnershipInterests	759000	usd
CY2023	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	3366000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3811229	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.80
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	342350	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.76
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	417379	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.09
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3051500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.17
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5300000	usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	207452	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.75
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	195607	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.77
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2648441	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.38
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	163824	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.75
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	68252	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.75
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2416365	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.54
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6600000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2416365	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.54
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6600000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	32300000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26822000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31847000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28412000	usd
	amrx	Percentage Of Tax Benefits Under Tax Receivable Agreement PercentageOfTaxBenefitsUnderTaxReceivableAgreement	0.85
	amrx	Percentage Of Tax Benefits Under Tax Receivable Agreement PercentageOfTaxBenefitsUnderTaxReceivableAgreement	0.85
CY2023Q4	amrx	Percentage Of Tax Benefits Under Tax Receivable Agreement PercentageOfTaxBenefitsUnderTaxReceivableAgreement	0.75
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	9900000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	9500000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	8900000	usd
CY2019Q1	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	0	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023	amrx	Number Of Product Families NumberOfProductFamilies	260	product
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2393607000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1573042000	usd
CY2023	us-gaap	Gross Profit GrossProfit	820565000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	429675000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	163950000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	30800000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	3828000	usd
CY2023	us-gaap	Restructuring Charges RestructuringCharges	1749000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	14497000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-1824000	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1138000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	204374000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2212304000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1427596000	usd
CY2022	us-gaap	Gross Profit GrossProfit	784708000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	399700000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	195688000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	12970000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	4358000	usd
CY2022	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	709000	usd
CY2022	us-gaap	Restructuring Charges RestructuringCharges	1421000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-731000	usd
CY2022	us-gaap	Insurance Recoveries InsuranceRecoveries	1911000	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-269930000	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	3960000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-94928000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2093669000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1324696000	usd
CY2021	us-gaap	Gross Profit GrossProfit	768973000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	365504000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	201847000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	710000	usd
CY2021	us-gaap	Royalty Expense RoyaltyExpense	7716000	usd
CY2021	amrx	Business Combination Acquisition Related Costs Transaction Related And Integration Expense BusinessCombinationAcquisitionRelatedCostsTransactionRelatedAndIntegrationExpense	8055000	usd
CY2021	us-gaap	Restructuring Charges RestructuringCharges	1857000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-200000	usd
CY2021	amrx	Charges For Property Losses And Associated Expense Net ChargesForPropertyLossesAndAssociatedExpenseNet	5368000	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-25000000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	152716000	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	550137000	usd
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	589360000	usd
CY2021Q3	amrx	Number Of Facilities Damaged NumberOfFacilitiesDamaged	2	facility
CY2021	us-gaap	Unusual Or Infrequent Item Loss Gross UnusualOrInfrequentItemLossGross	10400000	usd
CY2022	us-gaap	Insurance Recoveries InsuranceRecoveries	1900000	usd
CY2021	us-gaap	Insurance Recoveries InsuranceRecoveries	5000000	usd
CY2023	us-gaap	Unusual Or Infrequent Item Loss Gross UnusualOrInfrequentItemLossGross	0	usd
CY2022	us-gaap	Unusual Or Infrequent Item Loss Gross UnusualOrInfrequentItemLossGross	0	usd
CY2021	us-gaap	Unusual Or Infrequent Item Loss Gross UnusualOrInfrequentItemLossGross	10368000	usd
CY2023	us-gaap	Unusual Or Infrequent Item Insurance Proceeds UnusualOrInfrequentItemInsuranceProceeds	0	usd
CY2022	us-gaap	Unusual Or Infrequent Item Insurance Proceeds UnusualOrInfrequentItemInsuranceProceeds	1911000	usd
CY2021	us-gaap	Unusual Or Infrequent Item Insurance Proceeds UnusualOrInfrequentItemInsuranceProceeds	5000000	usd
CY2023	us-gaap	Unusual Or Infrequent Item Net Of Insurance Proceeds UnusualOrInfrequentItemNetOfInsuranceProceeds	0	usd
CY2022	us-gaap	Unusual Or Infrequent Item Net Of Insurance Proceeds UnusualOrInfrequentItemNetOfInsuranceProceeds	-1911000	usd
CY2021	us-gaap	Unusual Or Infrequent Item Net Of Insurance Proceeds UnusualOrInfrequentItemNetOfInsuranceProceeds	5368000	usd

Files In Submission

Name	View Source	Status
0001723128-24-000014-index-headers.html	Edgar Link	pending
0001723128-24-000014-index.html	Edgar Link	pending
0001723128-24-000014.txt	Edgar Link	pending
0001723128-24-000014-xbrl.zip	Edgar Link	pending
amrx-20231231.htm	Edgar Link	pending
amrx-20231231.xsd	Edgar Link	pending
amrx-2023123110xkex42xdesc.htm	Edgar Link	pending
amrx-2023123110xkexx231.htm	Edgar Link	pending
amrx-2023123110xkexx311.htm	Edgar Link	pending
amrx-2023123110xkexx312.htm	Edgar Link	pending
amrx-2023123110xkexx313.htm	Edgar Link	pending
amrx-2023123110xkexx321.htm	Edgar Link	pending
amrx-2023123110xkexx322.htm	Edgar Link	pending
amrx-2023123110xkexx323.htm	Edgar Link	pending
amrx-2023123110xkexx971xcl.htm	Edgar Link	pending
amrx-20231231_g1.jpg	Edgar Link	pending
amrx2023311210-kexx211.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
amrx-20231231_cal.xml	Edgar Link	unprocessable
amrx-20231231_def.xml	Edgar Link	unprocessable
amrx-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
amrx-20231231_htm.xml	Edgar Link	completed
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R135.htm	Edgar Link	pending
R136.htm	Edgar Link	pending
R137.htm	Edgar Link	pending
R138.htm	Edgar Link	pending
R139.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
amrx-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMRX
Amneal Pharmaceuticals, Inc. Stock $amrx

2024 Q1 Form 10-K Financial Statement

#000172312824000014 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRX Amneal Pharmaceuticals, Inc. Stock $amrx

2024 Q1 Form 10-K Financial Statement

#000172312824000014 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRX
Amneal Pharmaceuticals, Inc. Stock $amrx